Journal
CURRENT OSTEOPOROSIS REPORTS
Volume 13, Issue 6, Pages 399-406Publisher
SPRINGER
DOI: 10.1007/s11914-015-0291-y
Keywords
Osteoarthritis; NGF; Musculoskeletal pain; Pain mechanisms; Central sensitization
Categories
Funding
- NIH-NIAMS [R01 AR064850]
- Forest Research Institute
- Merck
- Novartis
- Perrigo
Ask authors/readers for more resources
Pain from osteoarthritis (OA) affectsmillions of people worldwide, yet treatments are limited to acetaminophen, NSAIDs, physical therapy, and ultimately, surgery when there is significant disability. In recent years, our understanding of pain pathways in OA has developed considerably. Though joint damage and inflammation play a significant role in pain generation, it is now understood that both central and peripheral nervous system mechanisms exacerbate symptoms. Evolving management strategies for OA address central factors (e.g., sleep difficulties, catastrophizing, and depression) with treatments such as cognitive behavioral therapy and exercise. In addition, emerging data suggest that antibodies against peripheral signaling neuropeptides, such as nerve growth factor-1 (NGF-1), may significantly alleviate pain. However, concerns regarding potential adverse effects, such as rapidly progressive OA, still remain. A nuanced understanding is essential if we are to make headway in developing more effective treatments for OA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available